In this video, Isabel shares how watching her children and grandchildren grow up inspires her to take the necessary steps to manage her life with type 2 diabetes and heart disease.
Our goal of transforming the treatment of neuroendocrine carcinomas
Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.